VYNE Therapeutics declares special cash dividend with Yarrow Bioscience merger

VYNE Therapeutics announced that its board of directors has declared a special cash dividend in connection with the previously announced merger with Yarrow Bioscience, pursuant to the agreement and plan of merger and reorganization, dated December 17, 2025. The cash dividend, which VYNE estimates will be an aggregate of $16.5M, or an estimated 38c per share, will be payable in cash to the stockholders and warrant holders of record as of July 22. The estimated per share dividend is based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9. The total actual distribution of the amount of the cash dividend is scheduled to be paid to VYNE's transfer agent, in accordance with the merger agreement, on July 23, and may be higher or lower than the estimated amount. The transfer agent will distribute the cash dividend to stockholders and warrant holders within a few days following the dividend payment date. Payment of the cash dividend is conditioned upon the closing of the merger. Closing is expected to occur on or about July 24, assuming that the transaction is approved by the company's stockholders and the satisfaction or waiver of all.